Tag: placebo

Being unable to walk quickly can be frustrating and problematic, but it is a common issue, especially as people age. Noting the pervasiveness of slower-than-desired walking, engineers at Stanford University have tested how well a prototype exoskeleton system they have developed – which attaches around the shin and into a running shoe – increased the

A phase 2 clinical trial whose results were released today in STEM CELLS Translational Medicine might point to a way to overcome bronchopulmonary dysplasia (BPD), a major cause of death in preterm infants. The study, conducted by researchers at Samsung Medical Center, Sungkyunkwan University and Asan Medical Center Children's Hospital in Seoul, evaluates the effectiveness

A drug approved for diabetes has now been shown to also help patients with diabetes lose on average 10 percent of their body weight, UT Southwestern reports in a landmark international study. Semaglutide, an injectable medication taken once a week, offers a nonsurgical way to reduce weight and treat obesity. It could help the more

In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Results of the Phase III clinical trial, conducted by an international team led by senior author Atul Malhotra, MD, research chief

A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and

(HealthDay)—Tirbanibulin is superior to vehicle at two months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year, according to a study published in the Feb. 11 issue of the New England Journal of Medicine. Andrew Blauvelt, M.D., from the Oregon Medical

In a clinical trial testing whether a daily regimen of hydroxychloroquine could protect those most likely to be exposed to COVID-19, researchers from the Perelman School of Medicine at the University of Pennsylvania found there was no difference in infection rates among health care workers who took the drug versus those taking a placebo. While

(HealthDay)—The selective Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, according to a study published May 10 in the New England Journal of Medicine to coincide with the annual meeting of the

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings. The research, led by scientists from Imperial College London and published in the Journal of the American Medical Association, studied three types of diabetes treatment: sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like